On October 3, 2011, FDA issued a draft guidance entitled, “De Novo Classification Process (Evaluation of Automatic Class III Designation).” In the guidance, FDA described the submission and review of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results